Evaluation of adherence, persistence and efficacy of treatment with Inclisiran in a real-life Italian population
Patients under Inclisiran treatment
Age < 18 years o > 80 years
Patients who refuse to participate and to sign informed consent
The study population includes patients from Italy, who have received Inclisiran as part of routine clinical management of their hyperlipidaemia, based on national reimbursement criteria, at time of enrollment
Case-only
Other
Inclisiran
DrugInjection
Description of adherence to treatment with Inclisiran in a real-life Italian population
Adherence will be assessed in terms of Medical Possession Ratio (MPR) which is defined as the ratio between the treatment units dispensed during the treatment period and the duration of the treatment period itself.
Description of persistence to treatment with Inclisiran in a real-life Italian population
Persistence will be assessed in terms of therapeutic continuity from the start of treatment to enrollment.
Description of efficacy of treatment with Inclisiran in a real-life Italian population
Efficacy of treatment will be evaluated as a change in the LDL (deltaLDL) value from the start of treatment (percentage and absolute value). The deltaLDL will be calculated as an overall (mean and median value), by type of prevention (primary and secondary), by type of basic therapy, by demographic variables (age, sex, geographic origin, basal LDL levels) and by type of prescriber (hospital or territorial).
Click on the lead sponsor to view all of their trials.
